What type of drug is penicillamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Penicillamine is a chelating agent and disease-modifying antirheumatic drug (DMARD) that works by binding to metals in the body, particularly copper, lead, and mercury, allowing them to be excreted in urine. This chelating property makes it effective for treating Wilson's disease, where it helps remove excess copper from the body 1. Penicillamine is also used to treat certain forms of rheumatoid arthritis due to its immunomodulatory effects, which can reduce inflammation and slow disease progression 1. Additionally, it can be prescribed for cystinuria, a condition where it helps prevent kidney stone formation by binding to cystine.

The typical dosage ranges from 250mg to 1500mg daily, depending on the condition being treated, and it's usually taken on an empty stomach to maximize absorption 1. Common side effects include rash, loss of taste, nausea, and reduced white blood cell count. Regular blood monitoring is essential during treatment to check for potential adverse effects on kidney function and blood cell counts 1. It's also important to note that penicillamine can cause severe side effects, such as nephrotoxicity, bone marrow toxicity, and dermatologic toxicities, which may require discontinuation of the drug 1.

Some key points to consider when prescribing penicillamine include:

  • Starting with incremental doses to enhance tolerability
  • Administering the drug 1 hour prior to or 2 hours after meals to minimize absorption interference
  • Regularly monitoring 24-hour urinary copper excretion to assess treatment efficacy
  • Providing supplemental pyridoxine to prevent deficiency
  • Being aware of the potential for severe side effects and adjusting treatment accordingly

Overall, penicillamine is a valuable treatment option for Wilson's disease and other conditions involving metal toxicity, but its use requires careful consideration of the potential benefits and risks, as well as close monitoring of patients to minimize adverse effects 1.

From the FDA Drug Label

Penicillamine is 3-mercapto-D-valine, a disease modifying antirheumatic drug. The type of drug is a disease modifying antirheumatic drug 2.

  • Key characteristics:
    • Freely soluble in water
    • Slightly soluble in alcohol
    • Insoluble in ether, acetone, benzene, and carbon tetrachloride
  • Chemical properties:
    • Empirical formula: C5H11NO2S
    • Molecular weight: 149.21
    • Structural formula: reacts readily with formaldehyde or acetone to form a thiazolidine-carboxylic acid

From the Research

Type of Drug

Penicillamine is classified as a:

  • Chelating agent, specifically a heavy metal chelator 3, 4, 5
  • Disease Modifying Antirheumatic Drug (DMARD) 6

Uses

The drug is used to treat various conditions, including:

  • Wilson's disease, an autosomal recessive disorder characterized by excessive accumulation of copper in the liver and other organs 3, 4, 5
  • Rheumatoid arthritis, a severe disease that can cause joint destruction and radiological progression 4, 7, 6
  • Cystinuria, a condition characterized by the formation of cystine stones in the kidneys 4
  • Systemic sclerosis, a dermatologic condition 4

Mechanism of Action

Penicillamine acts as a reductive chelator, binding to heavy metals such as copper and removing them from the body 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study].

Zhonghua er ke za zhi = Chinese journal of pediatrics, 2003

Research

[Gold compounds and D-penicillamine for therapy of rheumatoid arthritis].

Nihon rinsho. Japanese journal of clinical medicine, 1992

Research

Penicillamine-induced dermatomyositis. A case history.

Scandinavian journal of rheumatology, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.